Published July 7, 2006 | Version v1
Journal article

Vasohibin prevents arterial neointimal formation through angiogenesis inhibition

  • 1. Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai (Japan)
  • 2. Department of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai (Japan)
  • 3. Department of Pathology, Tohoku University Hospital, Sendai (Japan)
  • 4. Diagnostics Science Division, Shionogi and Co. Ltd, Osaka 561-0825 (Japan)

Description

Vasohibin is a VEGF-inducible angiogenesis inhibitor in vascular endothelium. Here we examined the presence of vasohibin in human arterial wall, and found it in endothelium of adventitial microvessels in atherosclerotic lesion. Adventitial angiogenesis is involved in the progression of neointimal formation. Even in the presence of endogenous angiogenesis inhibitors, pathological angiogenesis persists. However, the supplementation of exogenous angiogenesis inhibitors can prevent pathological angiogenesis. We evaluated the potential role of vasohibin in neointimal formation. Adenovirus-mediated human vasohibin gene transfer in mouse liver resulted in the release of vasohibin in plasma and exhibited anti-angiogenic effects at remote sites. This gene transfer inhibited adventitial angiogenesis, macrophage infiltration, and neointimal formation after cuff placement on mouse femoral artery. Vasohibin exhibited no direct effect on migration and proliferation of smooth muscle cells. Thus, vasohibin has an activity to prevent neointimal formation by inhibiting adventitial angiogenesis

Additional details

Identifiers

DOI
10.1016/j.bbrc.2006.04.176;
PII
S0006-291X(06)01021-7;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
345
Journal Issue
3
Journal Page Range
p. 919-925
ISSN
0006-291X
CODEN
BBRCA9

Optional Information

Copyright
Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.